KLA CORP（KLAC）の決算・業績分析
KLA CORPの2025年有価証券報告書をAI分析。売上高$12.2B(+23.9%)。Health Care。
目次
KLA CORPの2025年度 業績サマリー
KLA CORP（証券コード: KLAC）の2025年度決算・業績分析。売上高は$12.2B（前年比+23.9%）。純利益は$4.1B（前年比+47.1%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
KLA CORPの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue surged to $9.2B (+33.1% YoY) with net income jumping 59.8% to $3.3B (XBRL).
- ROE reached 113.8% (XBRL), reflecting strong equity returns despite a high D/E ratio of 3.82x (XBRL).
- Free cash flow (FCF) hit $3.0B, driven by $3.3B operating cash flow and $307M CapEx (XBRL).
- Share repurchases totaled $4.0B, offsetting $733M in dividends (XBRL).
KLA CORPの売上高変化の要因
- •FY2024 revenue of $9.2B reflects a 33.1% YoY increase and a 5-year CAGR of 21.1% (XBRL). Historical data shows consistent growth from $4.0B (FY2020) to $9.2B (FY2024), with no segment-specific revenue breakdown provided (XBRL). Growth drivers include strong demand in semiconductor manufacturing, though segment-level performance details are absent (XBRL).
KLA CORPの営業利益変化の要因
- •Operating income of $3.7B and EBITDA of $4.0B (43.6% margin) highlight robust profitability (XBRL). Net income rose 59.8% YoY to $3.3B, with net margins at 36.1% and operating margins at 39.7% (XBRL). Gross profit data is not available (XBRL).
KLA CORPの事業リスクと対応
Global economic downturns could reduce demand for electronic devices (10-K).
International operations face risks from tariffs, payment delays, and foreign currency fluctuations (10-K).
Intellectual property disputes may restrict product sales in certain regions (10-K).
ESG-related costs and regulatory pressures could impact operations (10-K).
High R&D expenses ($1.1B) and reliance on third-party service providers pose operational risks (XBRL).
KLA CORPの今後の見通し・業績予想
KLA CORPの事業内容
KLA Corp provides advanced process control and process-enabling solutions for semiconductor, PCB, and related component manufacturing, primarily through equipment sales, software licenses, and service contracts (10-K). Its three core segments are: (1) Semiconductor Process Control (inspection/metrology tools for IC/wafer manufacturing), (2) Specialty Semiconductor Process (vacuum deposition/etch tools for MEMS, RF, and power semiconductors), and (3) PCB and Component Inspection (inspection/testing solutions for PCBs and packaged ICs) (10-K). Competitive advantages include a comprehensive portfolio of process control solutions, proprietary software, and industry expertise since 1975 (10-K).
KLA CORPのAI業績分析レポート（2024年度）
KLA Corp (KLAC) FY2024 Annual Report Analysis
Highlights
Business Overview
KLA Corp provides advanced process control solutions for semiconductor, PCB, and related component manufacturing through equipment sales, software licenses, and service contracts (10-K). Key segments include Semiconductor Process Control, Specialty Semiconductor Process, and PCB/Component Inspection (10-K). Competitive advantages include proprietary software, industry expertise, and a comprehensive product portfolio (10-K).
Revenue Analysis
FY2024 revenue of $9.2B reflects a 33.1% YoY increase and 5-year CAGR of 21.1% (XBRL). Historical growth from $4.0B (FY2020) to $9.2B (FY2024) is consistent, though segment-specific revenue data is unavailable (XBRL).
Profitability Analysis
Operating income of $3.7B and EBITDA of $4.0B (43.6% margin) highlight strong profitability (XBRL). Net income rose 59.8% YoY to $3.3B, with net margins at 36.1% and operating margins at 39.7% (XBRL). Gross profit data is not available (XBRL).
Balance Sheet Analysis
Total assets grew to $14.1B (FY2024) from $9.0B (FY2020) (XBRL). Equity ratio of 20.8% and net debt of $4.0B (1.0x EBITDA) indicate high leverage (XBRL). Current ratio of 2.24x suggests strong liquidity, though long-term debt stands at $5.9B (XBRL).
Cash Flow Analysis
Operating cash flow reached $3.3B, with FCF of $3.0B after $307M in CapEx (XBRL). Investing cash flow was -$876M, while financing cash flow was -$2.3B, driven by $4.0B in share repurchases and $733M in dividends (XBRL).
Working Capital Analysis
CCC of 326 days reflects 72 days receivables, 292 days inventory, and 38 days payables (XBRL). Asset turnover of 0.65x indicates moderate efficiency (XBRL).
Risks
Outlook
Management guidance and forward-looking trends are not explicitly detailed in the provided data (10-K). Historical revenue projections suggest continued growth, with FY2025 revenue estimated at $10.5B (XBRL).
Health Careの企業一覧
KLA CORPと同じ「Health Care」セクターの企業